Molecular Templates, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Income (Loss) Per Common Share (Tables)

Net Income (Loss) Per Common Share (Tables)

12 Months Ended

Dec. 31, 2016

Reconciliation of Numerator and Denominator

A reconciliation of the numerator and denominator used in the calculation is as follows (in thousands, except per share amounts):

	Years Ended December 31,
	2016			2015		2014
Numerator:
Net income (loss) - basic	$	(24,094	)	$	43,822	$	(21,584	)
Less: noncash income from change in fair value of common stock warrants		—			3,906		9,344
Net income (loss) - diluted		(24,094	)		39,916	$	(30,928	)
Denominator:
Weighted-average number of common shares outstanding		71,524			70,242		60,335
Dilutive effect of equity incentive awards		—			1,873		—
Dilutive effect of warrants		—			1,368		3,051
Weighted-average common shares outstanding and dilutive potential common share-diluted		71,524			73,483		63,386
Net income (loss) per share:
Basic	$	(0.34	)	$	0.62	$	(0.36	)
Diluted	$	(0.34	)	$	0.54	$	(0.49	)

Warrants, Options and Purchase Rights Excluded from Computation of Diluted Net Income (Loss) Per Share

The following warrants, outstanding options and purchase rights under the Company’s 2004 Employee Stock Purchase Plan (“2004 Purchase Plan”) were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have had an antidilutive effect (in thousands)

	Years Ended December 31,
	2016		2015		2014
Shares issuable upon exercise of warrants		8,300		8,300		—
Shares issuable upon exercise of stock options		10,942		6,750		8,169
Shares issuable related to the ESPP		31		34		67